No abstract

The new benzodiazepine bromazepam (Ro 5-3350, Lexotan®) was compared with diazepam in a double-blind, crossover trial on 30 patients with prolonged anxiety symptoms. Each drug was given for 3 weeks in a dose of 5 mg t.d.s. Bromazepam proved to be statistically significantly superior to diazepam when evaluated through patients’ preferences. Fourteen patients preferred bromazepam to diazepam and four the opposite. Three cases were tied. Nine patients had to be withdrawn from the evaluation, which may create bias. A plea is made for further controlled clinical trials on bromazepam, in particular in obsessive and phobic neurosis.

No abstract

En pilotundersagelse af et nyt monoaminooxydasehaemmende forsagspraeparat (Ro 4-1038 Hoffmann-La Roche) J#rgen Remuig og Lass M . Sonne (Kdbenhavn) Elektroshocks vaxdi ved behandlingnavnlig af de typiske endogene depressionerer uomtvistelig. Alene ordets skraemmende virkning, men navnlig den ti1 tider ret generende piivirkning af hukommelsesfunktionen, har imidlertid gjort det Bnskeligt at finde en medicamentel erstatning for shockbehandlingen. I sin moderne udformning med narcose og anticonvulsiv Fra Rigshospitalets psykiatriske klinik. Chef: Professor, dr. med. Villars Lunn. Nord J Psychiatry Downloaded from informahealthcare.com by Nyu Medical Center on 02/05/15 For personal use only.

No abstract